Systematic review: Histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative

• Published in: Journal of Crohn's and colitis 2014-12, Vol.8 (12), p.1582-1597
• Main Authors: Bryant, R.V., Winer, S., SPL, Travis, Riddell, R.H.
• Format: Article
• Language: English
• Subjects: Clinical Trials as Topic; Endoscopy, Gastrointestinal; Histological healing; Histological indices; Histology; Humans; Inflammatory bowel disease; Inflammatory Bowel Diseases - pathology; Inflammatory Bowel Diseases - therapy; Intestinal Mucosa - pathology; Mucosal healing; Prognosis; Remission Induction; Ulcerative colitis; Wound Healing
• ISSN: 1873-9946; 1876-4479
• DOI: 10.1016/j.crohns.2014.08.011

Advances in the medical management of inflammatory bowel disease (IBD) have altered treatment targets. Endoscopic mucosal healing is associated with better outcomes in IBD, though less is known about the significance of achieving histological remission. Our aim was to perform a systematic review to investigate whether histological or ‘complete’ remission constitutes a further therapeutic target in IBD. A bibliographic search was performed on the 1st of October 2013 and subsequently on the 1st of March 2014 of online databases (OVID SP MEDLINE, OVID EMBASE, National Pubmed Central Medline, Cochrane Library, ISI, conference abstracts), using MeSH terms and key words: (“inflammatory bowel diseases” OR “crohn disease” OR “ulcerative colitis” OR “colitis”) AND (“mucosal healing” OR “histological healing” OR “pathological healing” OR “histological scoring” OR “pathological scoring”). The search returned 2951 articles. 120 articles were cited in the final analysis. There is no validated definition of histological remission in IBD. There are 22 different histological scoring systems for IBD, none of which are fully validated. Microscopic inflammation persists in 16–100% of cases of endoscopically quiescent disease. There is evidence that histological remission may predict risk of complications in ulcerative colitis beyond endoscopic mucosal healing, though data are scarce in Crohn's disease. Histological remission in IBD represents a target distinct from endoscopic mucosal healing, not yet routinely sought in clinical trials or practice. There remains a need for a standardized and validated histological scoring system and to confirm the prognostic value of histological remission as a treatment target in IBD.